Marta Martínez Vicente I am senior researcher at the VHIR, I’m a Principal Investigator at the Neurodegenerative Diseases Group and I head the Autophagy and Lysosomal Dysfunction lab. Instituciones de las que forman parte Investigador/a principal Enfermedades Neurodegenerativas Vall Hebron Institut de Recerca Marta Martínez Vicente Instituciones de las que forman parte Investigador/a principal Enfermedades Neurodegenerativas Vall Hebron Institut de Recerca I am senior researcher at the VHIR, I’m a Principal Investigator at the Neurodegenerative Diseases Group and I head the Autophagy and Lysosomal Dysfunction lab.
I obtained a degree in Chemistry/Biochemistry and a PhD in Biochemistry by the University of Valencia. From 2004 to 2008, I worked as a postdoctoral researcher at the laboratory of Dr. Ana Maria Cuervo at the Albert Einstein College of Medicine (New York, USA), focusing on the role of autophagy in neurodegenerative diseases and aging. I obtained in 2010 a tenure-track position as Miguel Servet I in the Neurodegenerative Diseases Group of the VHIR and since January 2016 I became VHIR Senior Researcher (Miguel Servet II-A). Currently, the efforts of my team are devoted to study the role of autophagy in neurodegeneration. Alterations in the autophagy process have been associated with neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimer’s disease and has been shown to be one of the main causes that contribute to neuronal death in these pathologies. Our efforts are currently directed to: 1) Study the role of the autophagic and lysosomal dysfunction in Parkinson’s disease; 2) Development of new therapies for Parkinson’s disease based in the restoration of lysosomal glucocerebrosidase (GBA) activity; 4) Unravel the link between Parkinson and lysosomal storage diseases, 4) Characterize the defective lysosomal-mediated turnover of mitochondria and aggregates in Huntington’s disease and its contribution to neurodegeneration. I’ve been able to turn my group into a reference group in the study of autophagy in neurodegeneration and aging. This position is endorsed by our publications, projects, dissemination activities and participation in scientific organizations. Bibliographic parameters: h-index: 31. Citations: >12.000, Publications: 49 scientific articles and mean impact factor/publication in the last 6 years = 10.6. I’ve been PI of several research projects funded by public agencies like ISCIII and MINECO as well as private entities as the Michael J. Fox Foundation, the Silverstein foundation and the BBVA Foundation, in addition I have also been PI in several collaboration agreements with private biotech companies. I’m member of the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), member and part of the management committee (board member) of the Spanish Autophagy Network (SEAFAGIA), member and part of the management committee of the European COST TRANSAUTOPHGAY network, member and part of the Scientific Advice Committee of the Women in Autophagy (WIA), member of the Spanish Society of Biochemistry and Molecular Biology (SEBBEM), and member of the Association of Women Researcher and Technologists (AMIT). As member of theses scientific societies I participated in the organization of national and international scientific conferences and I am member of the Editorial Board of Cells (ISSN 2073-440). I am in possession of the accreditation of Associate Professor/Researcher by the Agència per a Qualitat del Sistema Universitari de Catalunya (AQU).
Líneas de investigación Role of autophagy in neurodegeneration The main focus of our research is to study the role of autophagy in neurodegeneration. Autophagy is the degradation of intracellular components inside the lysosomes and it is essential for the maintenance of cellular homeostasis and neuronal viability. Alterations in the autophagy process have been associated with neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimer’s disease, and has been shown to be one of the main causes that contribute to neuronal death in these pathologies. Our efforts are currently directed to: - Study the pathogenic role of autophagic/lysosomal dysfunction in Parkinson's disease - Development of new therapies for Parkinson’s disease based in the restoration of lysosomal glucocerebrosidase (GBA) activity through nanoencapsulation. - Development of new autophagy pharmacological modulators (mTOR-independent) as a therapeutic strategy in neurodegenerative diseases. - Study selective autophagy in Huntington’s disease: charaterization of mitophagy impairment in Huntington’s disease. IP: Marta Martínez Vicente Pathogenic role of autophagic/lysosomal dysfunction in Parkinson's disease Autophagy is the degradation of intracellular components inside the lysosomes and it is essential for the maintenance of cellular homeostasis and neuronal viability. Alterations in the autophagy process have been associated with neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimer’s disease and has been shown to be one of the main causes that contribute to neuronal death in these pathologies. Our efforts are currently directed to: - Development of new therapies for Parkinson’s disease based in the restoration of lysosomal glucocerebrosidase (GBA) activity. - Development of new autophagy pharmacological modulators (mTOR-independent) as a therapeutic strategy in neurodegenerative diseases. IP: Marta Martínez Vicente, Miquel Vila Bover Mitophagy impairment in Huntington's disease Defective lysosomal-mediated turnover of mitochondria may play a pathogenic role in Huntington’s disease neurodegeneration. IP: Marta Martínez Vicente Proyectos Advancing Parkinson's disease management: targeting autophagic-lysosomal dysfunction for innovative diagnostics and therapeutics IP: Marta Martínez Vicente Colaboradores: José Antonio Arranz Amo, Mercedes Arrúe Gonzalo, Silvia Enriquez Calzada, Jorge Hernández Vara, Pau Sarle Valles, Eddie Pradas Gracia, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres, Jordi Riera Heredia, Pablo Castillo Sánchez Entidad financiadora: Instituto de Salud Carlos III Financiación: 265000 Referencia: PI24/00062 Duración: 01/01/2025 - 31/12/2027 NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease IP: Marta Martínez Vicente Colaboradores: Mercedes Arrúe Gonzalo, Maria Camprodon Gomez, Pablo Castillo Sánchez Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 42000 Referencia: 2024 PROD 00073 Duración: 02/12/2024 - 01/06/2026 NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson´s and Gaucher's disease IP: Marta Martínez Vicente Colaboradores: Mercedes Arrúe Gonzalo, Jorge Hernández Vara, Maria Camprodon Gomez, Jordi Riera Heredia, Pablo Castillo Sánchez Entidad financiadora: Fundació "La Caixa" Financiación: 24440 Referencia: CI24-20222 Duración: 01/10/2024 - 30/09/2026 Malalties neurodegeneratives IP: Miquel Vila Bover Colaboradores: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Malalties neurodegeneratives , Jordi Riera Heredia, Malalties neurodegeneratives , Helena Xicoy Cortada, Malalties neurodegeneratives , Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 40000 Referencia: 2021 SGR 00784 Duración: 01/01/2022 - 30/06/2025 Paginación Página actual 1 Página 2 Página 3 Página 4 Página 5 … Siguiente página › Última página »
